Piper Sandler | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  24898 of 24953  at  6/30/2020 10:24:47 AM  by

alias geo


Piper Sandler

Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $30 price target on Exelixis (EXEL) shares after the company initiated the Phase III CONTACT-02 study of CABOMETYX + Tecentriq in metastatic Castration-Resistant Prostate Cancer, one of three Phase III trials co-funded by Roche (RHHBY). Tenthoff says Exelixis intends to file for accelerated approval of cabo + Tencentriq in mCRPC based on expanded Cohort 6 data from COSMIC-021 in early 2021 and he expects Phase III COSMIC-312 1st-line liver cancer and COSMIC-311 Differentiated Thyroid Cancer data in 2H20.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 11     Views: 306
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
24899 Re: Piper Sandler indyengineer 4 6/30/2020 11:27:16 AM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...